Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Didanosine, Dose-Response Relationship, Drug, Drug Therapy, Combination, Stavudine, Hydroxyurea, Reverse Transcriptase Inhibitors, Anti-HIV Agents
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are HIV-positive. Have a viral load of 5,000 to 100,000 copies/ml. Are willing to stop all anti-HIV medications for at least 28 days before receiving study drugs. Are at least 18 years old. Exclusion Criteria Patients will not be eligible for this study if they: Have a history of opportunistic (AIDS-related) infection. Have a history of pancreatitis or other serious condition. Have any cancer that will require chemotherapy within the next 24 weeks. Are allergic to ddI or d4T. Have received an HIV vaccine within 28 days of study entry. Have received a red blood cell transfusion within the past 60 days, or have had repeated transfusions at any time in the past. Abuse alcohol or drugs. Have received certain medications.
Sites / Locations
- AIDS Healthcare Foundation
- San Francisco VA Med Ctr
- Gary Blick MD
- Dr Bruce Rashbaum
- IDC Research Initiative
- Boulevard Comprehensive Care Ctr
- Center for Quality Care
- AIDS Research Consortium of Atlanta Inc
- New England Med Ctr
- Albany Med College
- Mt Vernon Hosp
- Univ of Pennsylvania Med Ctr
- Thomas Jefferson Univ
- Coastal Carolina Research Ctr
- Univ of Texas Southwestern Med Ctr of Dallas
- Univ of Texas Med Branch
- Montrose Clinic
- Swedish Med Ctr